Literature DB >> 10910967

Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.

L Tessitore1, A Davit, I Sarotto, G Caderni.   

Abstract

We investigated whether resveratrol (RV) affects azoxymethane (AOM)-induced colon carcinogenesis, by administering RV (200 microg/kg/day in drinking water) to male F344 rats for 100 days, beginning 10 days before carcinogen treatment (two weekly doses of 15 mg/kg AOM). Aberrant crypt foci (ACF) were isolated and proliferation, apoptosis and expression of the cell cycle genes bax and p21 were determined. RV significantly reduced the number of ACF/colon [25.7 +/- 3.6 (mean +/- SEM) versus 39.4 +/- 3.3 in controls; P < 0.01] and their multiplicity (2.7 +/- 0.3 versus 4.9 +/- 0.6 in controls; P < 0.01), and also abolished large ACF. In RV-treated rats, bax expression was enhanced in ACF but not in the surrounding mucosa. In both controls and RV-treated rats, proliferation was higher in ACF than in normal mucosa. p21 was expressed in ACF of controls and of RV-treated rats and in normal mucosa of controls, but was lost in normal mucosa of RV-treated animals. In conclusion, the results suggest a protective role of RV in colon carcinogenesis with a mechanism involving changes in bax and p21 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910967

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  57 in total

Review 1.  Colorectal cancer: chemopreventive role of curcumin and resveratrol.

Authors:  Vaishali B Patel; Sabeena Misra; Bhaumik B Patel; Adhip P N Majumdar
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity.

Authors:  W D Johnson; R L Morrissey; A L Usborne; I Kapetanovic; J A Crowell; M Muzzio; D L McCormick
Journal:  Food Chem Toxicol       Date:  2011-09-10       Impact factor: 6.023

3.  Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.

Authors:  Juma Hoshino; Eun-Jung Park; Tamara P Kondratyuk; Laura Marler; John M Pezzuto; Richard B van Breemen; Shunyan Mo; Yongchao Li; Mark Cushman
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 4.  Role of phytochemicals in colorectal cancer prevention.

Authors:  Yu-Hua Li; Yin-Bo Niu; Yang Sun; Feng Zhang; Chang-Xu Liu; Lei Fan; Qi-Bing Mei
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

5.  Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma.

Authors:  Paula Ferrer; Miguel Asensi; Ramón Segarra; Angel Ortega; María Benlloch; Elena Obrador; María T Varea; Gregorio Asensio; Leonardo Jordá; José M Estrela
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

Review 6.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 7.  Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells.

Authors:  Mary Jo Atten; Ernesto Godoy-Romero; Bashar M Attar; Thomas Milson; Matthew Zopel; Oksana Holian
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

8.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.

Authors:  Jairam Vanamala; Lavanya Reddivari; Sridhar Radhakrishnan; Chris Tarver
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

9.  Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.

Authors:  Katarzyna Kupisiewicz; Patrice Boissy; Basem M Abdallah; Frederik Dagnaes Hansen; Reinhold G Erben; Jean-Francois Savouret; Kent Søe; Thomas L Andersen; Torben Plesner; Jean-Marie Delaisse
Journal:  Calcif Tissue Int       Date:  2010-09-15       Impact factor: 4.333

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.